Skip to main content

Jade Biosciences, Inc 10-Q for FY2026 Q3

Jade Biosciences, Inc. (JBIO)

10-Q 2026-11-13 For: 2026-09-30
View Original
Added on November 13, 2026

About this 10-Q

Jade Biosciences, Inc filed this 10-Q on November 13, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Jade Biosciences plans to initiate the JADE101 EVERGREEN Phase 3 trial in the fourth quarter of 2026. Net loss was $35.1 million for three months and $131.2 million for nine months ended September 30, 2026, while cash and investments totaled $475.7 million. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$35.06M
compared with a net loss of $25.18M a year earlier
Diluted EPS
-$0.42
compared with -$0.48 a year earlier